Cannabidiol - Echo Pharmaceuticals
Alternative Names: ArvisolLatest Information Update: 28 Feb 2024
At a glance
- Originator Echo Pharmaceuticals
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Anxiety disorders
- No development reported Epilepsy; Rett syndrome; Schizophrenia
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Rett syndrome in Netherlands (PO)
- 07 Jul 2021 Phase-II clinical trials in Anxiety disorders in Netherlands (PO) (EudraCT2020-004294-48)
- 22 Jun 2021 Centre for Human Drug Research plans a clinical trial for Neuropathic pain (In volunteers) in Netherlands (PO) (NL9543)